EP
NBIX icon

Eversept Partners’s Neurocrine Biosciences NBIX Stock Holding History

Eversept Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-167,243
Closed -$18.5M – 70
2025
Q1 		$18.5M Buy
+167,243
New +$21.2M 1.88% 19

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eversept Partners's NBIX Position: Q2 2025 in Review

Eversept Partners sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 167,243 shares — an estimated $18.5M sold.

Eversept Partners first reported a position in NBIX in Q1 2025 and held it in 1 quarter. The position peaked at $18.5M in Q1 2025. 586 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

  • Eversept Partners reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
  • Eversept Partners sold 167,243 Neurocrine Biosciences shares in Q2 2025, an estimated $18.5M.
  • Eversept Partners first reported a position in Neurocrine Biosciences in Q1 2025 and held it in 1 quarter.
  • Eversept Partners's Neurocrine Biosciences position peaked at $18.5M in Q1 2025.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on Eversept Partners's 13F filing for Q2 2025, filed 14 Aug 2025.